tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

Astellas Pharma Reports Record Revenue and Growth
Company AnnouncementsAstellas Pharma Reports Record Revenue and Growth
3d ago
Astellas Pharma Reports Higher Than Expected Financial Results
PremiumCompany Announcements
Astellas Pharma Reports Higher Than Expected Financial Results
7d ago
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
9d ago
FDA Approves Extended Use of Astellas’ IZERVAY for Geographic Atrophy
PremiumCompany Announcements
FDA Approves Extended Use of Astellas’ IZERVAY for Geographic Atrophy
3M ago
Astellas Pharma Reports Extraordinary Losses in Non-Consolidated Financial Results
PremiumCompany Announcements
Astellas Pharma Reports Extraordinary Losses in Non-Consolidated Financial Results
3M ago
Astellas Pharma’s Earnings Call: Mixed Outcomes and Strategic Shifts
PremiumCompany AnnouncementsAstellas Pharma’s Earnings Call: Mixed Outcomes and Strategic Shifts
3M ago
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
3M ago
Astellas Pharma Revises 2024 Financial Forecast Amid Core Business Growth and Impairment Losses
Premium
Company Announcements
Astellas Pharma Revises 2024 Financial Forecast Amid Core Business Growth and Impairment Losses
3M ago
Astellas Pharma’s Resubmission for IZERVAY Accepted by FDA
PremiumCompany Announcements
Astellas Pharma’s Resubmission for IZERVAY Accepted by FDA
4M ago
Astellas Faces FDA Setback on IZERVAY Application
PremiumCompany Announcements
Astellas Faces FDA Setback on IZERVAY Application
5M ago
Astellas Pharma Faces Currency Losses in FY2024
PremiumCompany Announcements
Astellas Pharma Faces Currency Losses in FY2024
6M ago
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ALPMF Earnings Report this Week: Is It a Buy, Ahead of Earnings?
6M ago
Astellas Pharma Withdraws EU Application for Key Drug
PremiumCompany AnnouncementsAstellas Pharma Withdraws EU Application for Key Drug
6M ago
Astellas Pharma’s VYLOY Gains FDA Approval for Cancer Treatment
Premium
Company Announcements
Astellas Pharma’s VYLOY Gains FDA Approval for Cancer Treatment
6M ago
Astellas’ New Cancer Therapy Gains Japan Approval
Premium
Company Announcements
Astellas’ New Cancer Therapy Gains Japan Approval
7M ago
Astellas Wins EU Approval for Advanced Cancer Drug
PremiumCompany Announcements
Astellas Wins EU Approval for Advanced Cancer Drug
7M ago
Bicycle says 45% of patients respond to bladder cancer drug, EN reports
PremiumThe Fly
Bicycle says 45% of patients respond to bladder cancer drug, EN reports
8M ago
MRK
PFE
Astellas Pharma Prices New Unsecured Bonds
PremiumCompany Announcements
Astellas Pharma Prices New Unsecured Bonds
8M ago
Astellas Gains EC Approval for Advanced Urothelial Cancer Treatment
PremiumCompany Announcements
Astellas Gains EC Approval for Advanced Urothelial Cancer Treatment
8M ago
New Urothelial Cancer Treatment Approved in China
PremiumCompany AnnouncementsNew Urothelial Cancer Treatment Approved in China
8M ago
Astellas Pharma Records ¥5.5 Billion Charge
Premium
Company Announcements
Astellas Pharma Records ¥5.5 Billion Charge
9M ago
ALPMF Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
ALPMF Upcoming Earnings Report: What to Expect?
9M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >